211 related articles for article (PubMed ID: 26262885)
1. Lenvatinib (Lenvima) for thyroid cancer.
Med Lett Drugs Ther; 2015 Aug; 57(1475):e120-1. PubMed ID: 26262885
[No Abstract] [Full Text] [Related]
2. [Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment].
Tsuruoka A; Matsui J; Suzuki T; Koyama N; Watanabe T; Funahashi Y
Nihon Yakurigaku Zasshi; 2015 Nov; 146(5):283-90. PubMed ID: 26558314
[No Abstract] [Full Text] [Related]
3. Lenvatinib improves survival in refractory thyroid cancer.
Mayor S
Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
[No Abstract] [Full Text] [Related]
4. Lenvatinib approved for certain thyroid cancers.
Cancer Discov; 2015 Apr; 5(4):338. PubMed ID: 25720434
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
6. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
8. Trial watch: Multikinase-targeting therapy finds potential niche in thyroid cancer.
Cully M
Nat Rev Drug Discov; 2015 Apr; 14(4):229. PubMed ID: 25829272
[No Abstract] [Full Text] [Related]
9. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
11. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
12. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine cancer: SELECT—lenvatinib in thyroid cancer.
Killock D
Nat Rev Clin Oncol; 2015 Apr; 12(4):189. PubMed ID: 25707627
[No Abstract] [Full Text] [Related]
14. Lenvatinib in radioiodine-refractory thyroid cancer.
Lee HJ; Yun HJ; Kim S
N Engl J Med; 2015 May; 372(19):1868. PubMed ID: 25946296
[No Abstract] [Full Text] [Related]
15. Lenvatinib in radioiodine-refractory thyroid cancer.
Schlumberger M; Tahara M; Wirth LJ
N Engl J Med; 2015 May; 372(19):1868. PubMed ID: 25946295
[No Abstract] [Full Text] [Related]
16. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib: first global approval.
Scott LJ
Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
[TBL] [Abstract][Full Text] [Related]
18. Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.
Dunn L; Fagin JA
Nat Rev Endocrinol; 2015 Jun; 11(6):325-7. PubMed ID: 25824678
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib receives approval in DTC.
J Nucl Med; 2015 Apr; 56(4):12N. PubMed ID: 25834176
[No Abstract] [Full Text] [Related]
20. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]